

## Invitation to Mendus in-person investor events with management

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, invites its investors and other stakeholders to meet in-person with Mendus CEO Erik Manting and CFO Lotta Ferm to discuss the company’s pipeline and outlook in the context of the current cancer immunotherapy landscape. Following a company presentation in English, there will be time for Q&A, followed by a “mix and mingle” for extended discussions. Please see below for details of the events:

### *Gothenburg*

Date and time: September 17, 18.00-20.00 CEST

Location: Clarion Hotel Post, Drottningtorget 10

### *Lund*

Date and time: September 18, 18.00-20.00 CEST

Location: Grand Hotel, Bantorget 1

### *Stockholm*

Date and time: September 19, 12.00-14.00 CEST

Location: Mendus Offices at Tändstickspalatset, Västra Trädgårdsgatan 15

“Mendus is at an exciting stage of its corporate development. We have made clear choices in our clinical development strategy, to adjust to the rapidly changing cancer immunotherapy landscape and focus on tumor recurrence as the main challenge in today’s treatment of cancer. Our pipeline has evolved accordingly, and we are well-positioned to continue developing our lead program vididendel as an active immunotherapy in acute myeloid leukemia. Also, our other pipeline programs are well-positioned to deliver additional upside for the company, its investors and, ultimately, patient benefit,” **says Mendus CEO Erik Manting**. “We look forward to interact in-person with the investors who follow-us on a regular basis and other interested stakeholders to reflect on the progress made, the insights gained and the way forward for the company.”

If you wish to join us and participate in one of the events, please send an email with your name and the event that you will attend, to: [ir@mendus.com](mailto:ir@mendus.com)

### **For more information, please contact:**

Erik Manting

Chief Executive Officer

E-mail: [ir@mendus.com](mailto:ir@mendus.com)

### **About Mendus AB (publ)**

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>